Pharmacoeconomics of subcutaneous allergen immunotherapy.

C. Incorvaia, F. Agostinis, S. Amoroso, R. Ariano, A. Barbato, M. Bassi, G. Cadario, P. Campi, F. Cardinale, C. Romano, G. Ciprandi, R. D'Anneo, S. Dal Bo, M. Di Gioacchino, A. Fiocchi, M. Galimberti, E. Galli, M. Giovannini, S. La Grutta, C. LombardiF. Marcucci, G. L. Marseglia, F. Mastrandrea, M. Minelli, E. Nettis, E. Novembre, C. Ortolani, G. Pajno, P. P. Piras, G. Passalacqua, G. Patriarca, S. Pucci, O. Quercia, A. Romano, D. Schiavino, M. Sforza, M. A. Tosca, S. Tripodi, M. Zambito, P. Puccinelli, F. Frati

Research output: Contribution to journalArticle

Abstract

The current burden of allergic diseases, estimated by both direct and indirect costs, is very relevant. In fact the cost estimation for rhinitis amount globally to 4-10 billion dollars/year in the U.S. and to an average annual cost of 1089 euros per child/adolescent and 1543 euros per adult in Europe. The estimated annual costs in Northern America for asthma amounted to 14 billion dollars. Consequently, preventive strategies aimed at reducing the clinical severity of allergy are potentially able to reduce its costs. Among them, specific immunotherapy (SIT) joins to the preventive capacity the carryover effect once treatment is discontinued. A number of studies, mainly conducted in the US and Germany demonstrated a favourable cost-benefit balance. In the nineties, most surveys on patients with allergic rhinitis and asthma reported significant reductions of the direct and indirect costs in subjects treated with SIT compared to those treated with symptomatic drugs. This is fully confirmed in recent studies conducted in European countries: in Denmark the direct cost per patient/year of the standard care was more than halved following SIT; in Italy a study on Parietaria allergic patients demonstrated a significant difference in favor of SIT plus drug treatment for three years versus drug treatment alone, with a cost reduction starting from the 2nd year and increasing to 48% at the 3rd year, with a highly statistical significance which was maintained up to the 6th year, i.e. 3 years after stopping immunotherapy, corresponding to a net saving for each patient at the final evaluation of 623 euros per year; in France a cost/efficacy analysis comparing SIT and current symptomatic treatment in adults and children with dust mite and pollen allergy showed remarkable savings with SIT for both allergies in adults and children.

Original languageEnglish
Pages (from-to)17-20
Number of pages4
JournalEuropean Annals of Allergy and Clinical Immunology
Volume39 Spec No
Publication statusPublished - 2007

Fingerprint

Immunologic Desensitization
Pharmaceutical Economics
Immunotherapy
Costs and Cost Analysis
Hypersensitivity
Asthma
Parietaria
Pharmaceutical Preparations
Seasonal Allergic Rhinitis
Mites
Denmark
Therapeutics
Standard of Care
Rhinitis
North America
Dust
Italy
France
Cost-Benefit Analysis
Germany

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Incorvaia, C., Agostinis, F., Amoroso, S., Ariano, R., Barbato, A., Bassi, M., ... Frati, F. (2007). Pharmacoeconomics of subcutaneous allergen immunotherapy. European Annals of Allergy and Clinical Immunology, 39 Spec No, 17-20.

Pharmacoeconomics of subcutaneous allergen immunotherapy. / Incorvaia, C.; Agostinis, F.; Amoroso, S.; Ariano, R.; Barbato, A.; Bassi, M.; Cadario, G.; Campi, P.; Cardinale, F.; Romano, C.; Ciprandi, G.; D'Anneo, R.; Dal Bo, S.; Di Gioacchino, M.; Fiocchi, A.; Galimberti, M.; Galli, E.; Giovannini, M.; La Grutta, S.; Lombardi, C.; Marcucci, F.; Marseglia, G. L.; Mastrandrea, F.; Minelli, M.; Nettis, E.; Novembre, E.; Ortolani, C.; Pajno, G.; Piras, P. P.; Passalacqua, G.; Patriarca, G.; Pucci, S.; Quercia, O.; Romano, A.; Schiavino, D.; Sforza, M.; Tosca, M. A.; Tripodi, S.; Zambito, M.; Puccinelli, P.; Frati, F.

In: European Annals of Allergy and Clinical Immunology, Vol. 39 Spec No, 2007, p. 17-20.

Research output: Contribution to journalArticle

Incorvaia, C, Agostinis, F, Amoroso, S, Ariano, R, Barbato, A, Bassi, M, Cadario, G, Campi, P, Cardinale, F, Romano, C, Ciprandi, G, D'Anneo, R, Dal Bo, S, Di Gioacchino, M, Fiocchi, A, Galimberti, M, Galli, E, Giovannini, M, La Grutta, S, Lombardi, C, Marcucci, F, Marseglia, GL, Mastrandrea, F, Minelli, M, Nettis, E, Novembre, E, Ortolani, C, Pajno, G, Piras, PP, Passalacqua, G, Patriarca, G, Pucci, S, Quercia, O, Romano, A, Schiavino, D, Sforza, M, Tosca, MA, Tripodi, S, Zambito, M, Puccinelli, P & Frati, F 2007, 'Pharmacoeconomics of subcutaneous allergen immunotherapy.', European Annals of Allergy and Clinical Immunology, vol. 39 Spec No, pp. 17-20.
Incorvaia C, Agostinis F, Amoroso S, Ariano R, Barbato A, Bassi M et al. Pharmacoeconomics of subcutaneous allergen immunotherapy. European Annals of Allergy and Clinical Immunology. 2007;39 Spec No:17-20.
Incorvaia, C. ; Agostinis, F. ; Amoroso, S. ; Ariano, R. ; Barbato, A. ; Bassi, M. ; Cadario, G. ; Campi, P. ; Cardinale, F. ; Romano, C. ; Ciprandi, G. ; D'Anneo, R. ; Dal Bo, S. ; Di Gioacchino, M. ; Fiocchi, A. ; Galimberti, M. ; Galli, E. ; Giovannini, M. ; La Grutta, S. ; Lombardi, C. ; Marcucci, F. ; Marseglia, G. L. ; Mastrandrea, F. ; Minelli, M. ; Nettis, E. ; Novembre, E. ; Ortolani, C. ; Pajno, G. ; Piras, P. P. ; Passalacqua, G. ; Patriarca, G. ; Pucci, S. ; Quercia, O. ; Romano, A. ; Schiavino, D. ; Sforza, M. ; Tosca, M. A. ; Tripodi, S. ; Zambito, M. ; Puccinelli, P. ; Frati, F. / Pharmacoeconomics of subcutaneous allergen immunotherapy. In: European Annals of Allergy and Clinical Immunology. 2007 ; Vol. 39 Spec No. pp. 17-20.
@article{92b7d32bf5f84a8fb66e6d128ff181a8,
title = "Pharmacoeconomics of subcutaneous allergen immunotherapy.",
abstract = "The current burden of allergic diseases, estimated by both direct and indirect costs, is very relevant. In fact the cost estimation for rhinitis amount globally to 4-10 billion dollars/year in the U.S. and to an average annual cost of 1089 euros per child/adolescent and 1543 euros per adult in Europe. The estimated annual costs in Northern America for asthma amounted to 14 billion dollars. Consequently, preventive strategies aimed at reducing the clinical severity of allergy are potentially able to reduce its costs. Among them, specific immunotherapy (SIT) joins to the preventive capacity the carryover effect once treatment is discontinued. A number of studies, mainly conducted in the US and Germany demonstrated a favourable cost-benefit balance. In the nineties, most surveys on patients with allergic rhinitis and asthma reported significant reductions of the direct and indirect costs in subjects treated with SIT compared to those treated with symptomatic drugs. This is fully confirmed in recent studies conducted in European countries: in Denmark the direct cost per patient/year of the standard care was more than halved following SIT; in Italy a study on Parietaria allergic patients demonstrated a significant difference in favor of SIT plus drug treatment for three years versus drug treatment alone, with a cost reduction starting from the 2nd year and increasing to 48{\%} at the 3rd year, with a highly statistical significance which was maintained up to the 6th year, i.e. 3 years after stopping immunotherapy, corresponding to a net saving for each patient at the final evaluation of 623 euros per year; in France a cost/efficacy analysis comparing SIT and current symptomatic treatment in adults and children with dust mite and pollen allergy showed remarkable savings with SIT for both allergies in adults and children.",
author = "C. Incorvaia and F. Agostinis and S. Amoroso and R. Ariano and A. Barbato and M. Bassi and G. Cadario and P. Campi and F. Cardinale and C. Romano and G. Ciprandi and R. D'Anneo and {Dal Bo}, S. and {Di Gioacchino}, M. and A. Fiocchi and M. Galimberti and E. Galli and M. Giovannini and {La Grutta}, S. and C. Lombardi and F. Marcucci and Marseglia, {G. L.} and F. Mastrandrea and M. Minelli and E. Nettis and E. Novembre and C. Ortolani and G. Pajno and Piras, {P. P.} and G. Passalacqua and G. Patriarca and S. Pucci and O. Quercia and A. Romano and D. Schiavino and M. Sforza and Tosca, {M. A.} and S. Tripodi and M. Zambito and P. Puccinelli and F. Frati",
year = "2007",
language = "English",
volume = "39 Spec No",
pages = "17--20",
journal = "Allergie et Immunologie",
issn = "0397-9148",
publisher = "Mattioli 1885 S.p.A.",

}

TY - JOUR

T1 - Pharmacoeconomics of subcutaneous allergen immunotherapy.

AU - Incorvaia, C.

AU - Agostinis, F.

AU - Amoroso, S.

AU - Ariano, R.

AU - Barbato, A.

AU - Bassi, M.

AU - Cadario, G.

AU - Campi, P.

AU - Cardinale, F.

AU - Romano, C.

AU - Ciprandi, G.

AU - D'Anneo, R.

AU - Dal Bo, S.

AU - Di Gioacchino, M.

AU - Fiocchi, A.

AU - Galimberti, M.

AU - Galli, E.

AU - Giovannini, M.

AU - La Grutta, S.

AU - Lombardi, C.

AU - Marcucci, F.

AU - Marseglia, G. L.

AU - Mastrandrea, F.

AU - Minelli, M.

AU - Nettis, E.

AU - Novembre, E.

AU - Ortolani, C.

AU - Pajno, G.

AU - Piras, P. P.

AU - Passalacqua, G.

AU - Patriarca, G.

AU - Pucci, S.

AU - Quercia, O.

AU - Romano, A.

AU - Schiavino, D.

AU - Sforza, M.

AU - Tosca, M. A.

AU - Tripodi, S.

AU - Zambito, M.

AU - Puccinelli, P.

AU - Frati, F.

PY - 2007

Y1 - 2007

N2 - The current burden of allergic diseases, estimated by both direct and indirect costs, is very relevant. In fact the cost estimation for rhinitis amount globally to 4-10 billion dollars/year in the U.S. and to an average annual cost of 1089 euros per child/adolescent and 1543 euros per adult in Europe. The estimated annual costs in Northern America for asthma amounted to 14 billion dollars. Consequently, preventive strategies aimed at reducing the clinical severity of allergy are potentially able to reduce its costs. Among them, specific immunotherapy (SIT) joins to the preventive capacity the carryover effect once treatment is discontinued. A number of studies, mainly conducted in the US and Germany demonstrated a favourable cost-benefit balance. In the nineties, most surveys on patients with allergic rhinitis and asthma reported significant reductions of the direct and indirect costs in subjects treated with SIT compared to those treated with symptomatic drugs. This is fully confirmed in recent studies conducted in European countries: in Denmark the direct cost per patient/year of the standard care was more than halved following SIT; in Italy a study on Parietaria allergic patients demonstrated a significant difference in favor of SIT plus drug treatment for three years versus drug treatment alone, with a cost reduction starting from the 2nd year and increasing to 48% at the 3rd year, with a highly statistical significance which was maintained up to the 6th year, i.e. 3 years after stopping immunotherapy, corresponding to a net saving for each patient at the final evaluation of 623 euros per year; in France a cost/efficacy analysis comparing SIT and current symptomatic treatment in adults and children with dust mite and pollen allergy showed remarkable savings with SIT for both allergies in adults and children.

AB - The current burden of allergic diseases, estimated by both direct and indirect costs, is very relevant. In fact the cost estimation for rhinitis amount globally to 4-10 billion dollars/year in the U.S. and to an average annual cost of 1089 euros per child/adolescent and 1543 euros per adult in Europe. The estimated annual costs in Northern America for asthma amounted to 14 billion dollars. Consequently, preventive strategies aimed at reducing the clinical severity of allergy are potentially able to reduce its costs. Among them, specific immunotherapy (SIT) joins to the preventive capacity the carryover effect once treatment is discontinued. A number of studies, mainly conducted in the US and Germany demonstrated a favourable cost-benefit balance. In the nineties, most surveys on patients with allergic rhinitis and asthma reported significant reductions of the direct and indirect costs in subjects treated with SIT compared to those treated with symptomatic drugs. This is fully confirmed in recent studies conducted in European countries: in Denmark the direct cost per patient/year of the standard care was more than halved following SIT; in Italy a study on Parietaria allergic patients demonstrated a significant difference in favor of SIT plus drug treatment for three years versus drug treatment alone, with a cost reduction starting from the 2nd year and increasing to 48% at the 3rd year, with a highly statistical significance which was maintained up to the 6th year, i.e. 3 years after stopping immunotherapy, corresponding to a net saving for each patient at the final evaluation of 623 euros per year; in France a cost/efficacy analysis comparing SIT and current symptomatic treatment in adults and children with dust mite and pollen allergy showed remarkable savings with SIT for both allergies in adults and children.

UR - http://www.scopus.com/inward/record.url?scp=55449102912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55449102912&partnerID=8YFLogxK

M3 - Article

C2 - 18924462

AN - SCOPUS:55449102912

VL - 39 Spec No

SP - 17

EP - 20

JO - Allergie et Immunologie

JF - Allergie et Immunologie

SN - 0397-9148

ER -